Exposure to dipeptidyl-peptidase-4 inhibitors andCOVID-19 among people with type 2 diabetes: A case-control study
Exposure to dipeptidyl-peptidase-4 inhibitors andCOVID-19 among people with type 2 diabetes: A case-control study
复制标题
DOI：
10.1111/dom.14097
复制
发表时间：
2020-07-01
影响因子：
5.8
通讯作者：
Avogaro, Angelo
中科院分区：
文献类型：
--
作者：
Fadini, Gian Paolo;Morieri, Mario Luca;Avogaro, Angelo
由于其他冠状病毒通过与二肽基肽酶-4（DPP-4）结合进入细胞，因此推测DPP-4抑制剂（DPP-4 is）可能对严重急性呼吸综合征冠状病毒2型发挥活性。在没有临床试验结果的情况下，我们分析了流行病学数据，以支持或放弃这种假设。我们检索了在意大利一家爆发疫情的医院因COVID-19住院的2型糖尿病（T2 D）患者中暴露于DPP-4 is的信息。作为参考，我们检索了同一地区匹配的T2 D患者中DPP-4 is暴露的信息。在403名住院的COVID-19患者中，有85名患有T2 D。T2 D合并COVID-19患者的DPP-4 is暴露率相似（10.6%）和14857例匹配患者（8.8%），或793例当地门诊匹配患者（15.4%），8284例匹配患者因其他原因住院（8.5%），并将71名因COVID-19肺炎住院的患者（11.3%）与351名患有其他病因肺炎的匹配患者（10.3%）进行比较。接受DPP-4 is治疗的COVID-19 T2 D患者的疾病结局与未接受DPP-4 is治疗的患者相似。总之，我们没有发现DPP-4 is可能影响COVID-19住院治疗的证据。
Because other coronaviruses enter the cells by binding to dipeptidyl-peptidase-4 (DPP-4), it has been speculated that DPP-4 inhibitors (DPP-4is) may exert an activity against severe acute respiratory syndrome coronavirus 2. In the absence of clinical trial results, we analysed epidemiological data to support or discard such a hypothesis. We retrieved information on exposure to DPP-4is among patients with type 2 diabetes (T2D) hospitalized for COVID-19 at an outbreak hospital in Italy. As a reference, we retrieved information on exposure to DPP-4is among matched patients with T2D in the same region. Of 403 hospitalized COVID-19 patients, 85 had T2D. The rate of exposure to DPP-4is was similar between T2D patients with COVID-19 (10.6%) and 14 857 matched patients in the region (8.8%), or 793 matched patients in the local outpatient clinic (15.4%), 8284 matched patients hospitalized for other reasons (8.5%), and when comparing 71 patients hospitalized for COVID-19 pneumonia (11.3%) with 351 matched patients with pneumonia of another aetiology (10.3%). T2D patients with COVID-19 who were on DPP-4is had a similar disease outcome as those who were not. In summary, we found no evidence that DPP-4is might affect hospitalization for COVID-19.